• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献>>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

Decrease in the Ki67 index during neoadjuvant chemotherapy predicts favorable relapse-free survival in patients with locally advanced breast cancer

摘要Objective: The purpose of this study was to explore the optimal cutoffs of the three parameters of Ki67 during NAC for predicting patient prognosis and investigate whether the optimal cutoffs of the Ki67 values were associated with relapse-free survival (RFS) or breast cancer-specific survival (BCSS). Methods: A total of 92 patients with locally advanced breast cancer (LABC), who had residual disease after NAC were retrospectively investigated. The optimal cutoff values of the Ki67 parameters were assessed by the online algorithm Cutoff Finder. Kaplan-Meier analysis, the log-rank test and Cox regression analysis were carried out to analyze survival. Results: The optimal cutoff values for the postsurgical Ki67 level and the decrease in the Ki67 level during NAC were defined as 25% and 12.5%, respectively. According to the univariate survival analysis, a higher Ki67 level in residual disease was associated with poor RFS (P = 0.004) and BCSS (P = 0.014). In addition, a Ki67 expression decrease > 12.5% during NAC was related to favorable RFS (P = 0.007), but was not related to BCSS (P = 0.452). Cox regression analysis showed that the Ki67 expression decrease (> 12.5% vs. ≤ 12.5%) and histological grade (grade 3 vs. grade 1-2) were the independent factors associated with RFS (P =0.020 and P = 0.023, respectively), with HR values of 0.353 (95% CI: 0.147-0.850) and 3.422 (95% CI: 1.188-9.858), respectively. Conclusions: The Ki67 decrease was one of the independent factors associated with RFS in LABC patients with residual disease after receiving NAC.

更多
广告
作者单位 Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, China [1] Department of Information, Cancer Hospital of Shantou University Medical College, Shantou 515031, China [2] The Breast Center, Cancer Hospital of Shantou University Medical College, Shantou 515031, China [3] Cancer Center, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361100, China;Changjiang Scholar's Laboratory, Cancer Hospital of Shantou University Medical College, Shantou 515031, China [4]
栏目名称
DOI 10.20892/j.issn.2095-3941.2018.0423
发布时间 2019-09-23
提交
  • 浏览20
  • 下载0
癌症生物学与医学(英文版)

癌症生物学与医学(英文版)

2019年16卷3期

575-586页

SCIMEDLINEISTICCSCDCABP

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷